Company Filing History:
Years Active: 2012-2013
Title: David Goldstein: Innovator in PI3K Inhibitor Compounds
Introduction
David Goldstein is a notable inventor based in Nutley, NJ (US). He has made significant contributions to the field of pharmaceutical compounds, particularly in the development of PI3K inhibitors. With a total of 3 patents to his name, Goldstein's work is pivotal in addressing various medical conditions.
Latest Patents
Goldstein's latest patents focus on bicyclic pyrimidine PI3K inhibitor compounds that are selective for the P110 delta isoform. These compounds, described in detail in his patents, are useful for inhibiting the delta isoform of PI3K and for treating disorders mediated by lipid kinases, such as inflammation, immunological issues, and cancer. The methods of using these compounds for in vitro, in situ, and in vivo diagnosis, prevention, or treatment of such disorders in mammalian cells are also disclosed.
Career Highlights
David Goldstein is currently associated with Genentech, Inc., where he continues to innovate and develop new therapeutic solutions. His expertise in the field has led to advancements that could potentially transform treatment protocols for various diseases.
Collaborations
Goldstein has collaborated with notable coworkers, including Georgette M Castanedo and Rama Kondru, contributing to a dynamic research environment that fosters innovation.
Conclusion
David Goldstein's work in developing PI3K inhibitor compounds showcases his commitment to advancing medical science. His contributions are essential in the ongoing fight against diseases influenced by lipid kinases.